SlideShare a Scribd company logo
ABSTRACT N0 -ABS0027
TITLE: CRTICAL ILLNESS POLYMYOPATHY IN COVID 19
PATIENTS.
AUTHORS: DR MOHAMMAD ABBAS, DR HARISH M M
NARAYANA HRUDAYALAYA HOSPITAL, BOMMASANDRA,
BENGALURU-560022
TITLE:CRTICAL ILLNESS POLYMYOPATHY IN COVID 19 PATIENTS.
INTRODUCTION:
COVID19disease aglobalpandemicwillberemembered for rapid onset respiratory failure
requiring Oxygen therapy, Prolonged Mechanical ventilation and Proning. It required
Prolonged duration of hospitalization, Inotropic supports, Antibiotics, Steroids,
Fluctuation in Sugar levels and prolonged use of muscle relaxants for mechanical
ventilation which is associated with increased incidence on Critical illness
polymyopathy.
Hence, we collected retrospective data of critically ill COVID-19 patients who
developed from critical illness myopathy and assessed the effect of various risk factors
and interventions like physiotherapy on the long-term outcome in these patients.
METHODOLOGY:
COVID19Positive
August2020–December2020
Criticalillnesspolymyopathyclinically
Anonymously, and all patient identifiers were removed to ensure confidentiality
DATA COLLECTION.
Demographic details, Vitals, dose of inotropes, Glasgow Coma Scale(GCS), SOFA scores
at arrival, Glucose levels, Arterial blood gas analysis, Complete blood count,
Electrolytes, and Use of antibiotics, Steroids, Hydroxychloroquine/chloroquine,
Antivirals were collected. Use of interventions, and Various physiotherapy
measures(re-education, long sitting on the bed, chair mobilization, walking, and gait
balance) in terms of outcomes.
TITLE:CRTICAL ILLNESS POLYMYOPATHY IN COVID 19 PATIENTS.
RESULTS.
RESULTS Survived (N= 7) Died (N= 4) P value
Age (yrs) 59 ± 1.41 63 ± 4.24 0.24
Male (%) 5 (71.4%) 3 (75%) 0.72
Female 2 (28.6%) 1(25%)
Weight, kg 80 ± 2.82 73±7.07 1
ICU stay* (No. of days) 41 (2) 26 (5) 0.57
Ventilator days 32.5 (11) 13 (1) 0.61
Ventilator Free days 9(15) 5(14.5) 0.67
P/F ratio† 179.57 ± 13.66 171 ± 39.04 0.60
PCO2, mmHg‡ 46.42 ± 7.43 48 ± 4.08 0.70
SOFA score§ 2.57 ± 0.97 2.75 ± 0.50 0.74
Neuromuscular relaxant Free
days 17(17) 13.5(23) 0.75
Corticosteroid use, days 15.1±3.3 20.2±5.6 0.08
Polymyxin use, days 7.8±5.3 7.5±3.5 0.90
Colchicine use, days 8.3±3.8 9.5±1.9 0.58
Random Blood Sugar, mg/dl 140.50 ± 7.78 188.50 ± 21.92 0.86
Lactate, mmol/L 1.57 ± 0.53 2.25 ± 0.50 0.06
CRP, mg/L||
92.50 ± 88.38 129 ± 152.73 0.50
LDH, Units/L** 641.50 ± 44.54 467.50 ± 567.80 0.24
Ferritin, ng/ml 565 ± 244.65 1042.50 ± 497.09 0.24
D-Dimer, ng/ml 2253 ± 654.78 2246 ± 2375.87 0.12
Survived (N= 7) Died (N= 4) P value
Re education, number
of days 16.29 ± 5.55 14.50 ± 4.12 0.59
Long Sitting, number of
days 10.43 ± 3.15 2.75 ± 3.09 0.007
Chair mobilization,
number of days 7.14 ± 1.95 2 ± 1.41 0.001
Standing, number of
days 3.43 ± 3.15 0 0.06
Survived
(N=7) Died (N=4) P value
Dependency, Total
(n,%) 1 (14.3%) 4 (100%) 0.02
Significant
(n,%) 5 (71.4%) 0
DISCUSSION:
One important finding in our case
series was the effect of protocol-based
physiotherapy interventions on
survival.
Physiotherapy
CONCLUSION:
In patients with COVID-19 related critical illness myopathy, use of protocol based
physiotherapy interventions leads to improved survival. Further studies with larger
population of cases are needed to draw a stronger conclusion.
REFERENCES: 1. Critical Illness Polyneuropathy and Myopathy in COVID-19 Patients: A Prospective Observational Intensive Care
Unit Cross-Sectional Cohort Study [Internet]. 2020 [cited 2021 Mar 18]. Available from: https://www.researchsquare.com.
2.Cabañes-Martínez L, Villadóniga M, González-Rodríguez L, Araque L, Díaz-Cid A, Ruz- Caracuel I, et al. Neuromuscular
involvement in COVID-19 critically ill patients. Clin Neurophysiol. 2020;131:2809–16.
TITLE:CRTICAL ILLNESS POLYMYOPATHY IN COVID 19 PATIENTS.
LIMITATIONS
Smaller sample size
Definitive diagnostic methods not used.

More Related Content

Similar to DR. MOHAMMAD ABBAS- E-POSTER PRESENTATION.pptx

Cypher Stent - SIRIUS Trial
Cypher Stent - SIRIUS TrialCypher Stent - SIRIUS Trial
Cypher Stent - SIRIUS Trial
MedicineAndFamily
 
Presentation to CCG - Capita Health Freakononics v3
Presentation to CCG - Capita Health Freakononics v3Presentation to CCG - Capita Health Freakononics v3
Presentation to CCG - Capita Health Freakononics v3
Mike Thorogood
 
Approaches to managing CV risk in patients with T2D.pptx
Approaches to managing CV risk in patients with T2D.pptxApproaches to managing CV risk in patients with T2D.pptx
Approaches to managing CV risk in patients with T2D.pptx
dtettam1
 
the po
the pothe po
the po
SoM
 
KAWASAKI DISEASE: A CASE REPORT
KAWASAKI DISEASE: A CASE REPORTKAWASAKI DISEASE: A CASE REPORT
KAWASAKI DISEASE: A CASE REPORT
PARUL UNIVERSITY
 
14:35 Yamane - Update Japanese Multicenter Registry
14:35 Yamane -  Update Japanese Multicenter Registry14:35 Yamane -  Update Japanese Multicenter Registry
14:35 Yamane - Update Japanese Multicenter Registry
Euro CTO Club
 
acyclovir-for-sarscov2-an-old-drug-with-a-new-purpose.pdf
acyclovir-for-sarscov2-an-old-drug-with-a-new-purpose.pdfacyclovir-for-sarscov2-an-old-drug-with-a-new-purpose.pdf
acyclovir-for-sarscov2-an-old-drug-with-a-new-purpose.pdf
ShaheenJan
 
Contrast induced-Acute Kidney Injury
Contrast induced-Acute Kidney InjuryContrast induced-Acute Kidney Injury
Contrast induced-Acute Kidney Injury
smujeeb11
 
11_Management Post operative Low Cardiac Output Syndrome.pdf
11_Management Post operative Low Cardiac Output Syndrome.pdf11_Management Post operative Low Cardiac Output Syndrome.pdf
11_Management Post operative Low Cardiac Output Syndrome.pdf
Asokjayaraj
 
Sepsis
SepsisSepsis
Sepsis
Amit Karnik
 
ueda2012 metabolic memory-d.mgahed
ueda2012 metabolic memory-d.mgahedueda2012 metabolic memory-d.mgahed
ueda2012 metabolic memory-d.mgahed
ueda2015
 
NSAIDs and ICON-G
NSAIDs and ICON-GNSAIDs and ICON-G
NSAIDs and ICON-G
Conrad Strydom
 
DCCT Learned Lessons
DCCT Learned LessonsDCCT Learned Lessons
DCCT Learned Lessons
Mohammad Othman Daoud
 
Hemodynamic Puzzle
Hemodynamic PuzzleHemodynamic Puzzle
Hemodynamic Puzzle
Mazen Yazan Kherallah
 
Nguyen huu hoang ta
Nguyen huu hoang taNguyen huu hoang ta
Nguyen huu hoang ta
Duy Quang
 
download-key-lessons-on-ldl-c-and-cv-risk.pptx
download-key-lessons-on-ldl-c-and-cv-risk.pptxdownload-key-lessons-on-ldl-c-and-cv-risk.pptx
download-key-lessons-on-ldl-c-and-cv-risk.pptx
UmaShanksr
 
Gliclazide - Revisiting evidence on a classic therapy - Dr. Rajiv Kovil.pptx
Gliclazide - Revisiting evidence on a classic therapy - Dr. Rajiv Kovil.pptxGliclazide - Revisiting evidence on a classic therapy - Dr. Rajiv Kovil.pptx
Gliclazide - Revisiting evidence on a classic therapy - Dr. Rajiv Kovil.pptx
AmeetRathod3
 
Treatment for severe acute respiratory distress syndrome from covid 19
Treatment for severe acute respiratory distress syndrome from covid   19Treatment for severe acute respiratory distress syndrome from covid   19
Treatment for severe acute respiratory distress syndrome from covid 19
Valentina Corona
 
Focus on long acting opioid substitution therapy.pptx
Focus on long acting opioid substitution therapy.pptxFocus on long acting opioid substitution therapy.pptx
Focus on long acting opioid substitution therapy.pptx
ehab elbaz
 
Rao SV - AIMRADIAL 2013 - Bivalirudin and radial
Rao SV - AIMRADIAL 2013 - Bivalirudin and radialRao SV - AIMRADIAL 2013 - Bivalirudin and radial
Rao SV - AIMRADIAL 2013 - Bivalirudin and radial
International Chair on Interventional Cardiology and Transradial Approach
 

Similar to DR. MOHAMMAD ABBAS- E-POSTER PRESENTATION.pptx (20)

Cypher Stent - SIRIUS Trial
Cypher Stent - SIRIUS TrialCypher Stent - SIRIUS Trial
Cypher Stent - SIRIUS Trial
 
Presentation to CCG - Capita Health Freakononics v3
Presentation to CCG - Capita Health Freakononics v3Presentation to CCG - Capita Health Freakononics v3
Presentation to CCG - Capita Health Freakononics v3
 
Approaches to managing CV risk in patients with T2D.pptx
Approaches to managing CV risk in patients with T2D.pptxApproaches to managing CV risk in patients with T2D.pptx
Approaches to managing CV risk in patients with T2D.pptx
 
the po
the pothe po
the po
 
KAWASAKI DISEASE: A CASE REPORT
KAWASAKI DISEASE: A CASE REPORTKAWASAKI DISEASE: A CASE REPORT
KAWASAKI DISEASE: A CASE REPORT
 
14:35 Yamane - Update Japanese Multicenter Registry
14:35 Yamane -  Update Japanese Multicenter Registry14:35 Yamane -  Update Japanese Multicenter Registry
14:35 Yamane - Update Japanese Multicenter Registry
 
acyclovir-for-sarscov2-an-old-drug-with-a-new-purpose.pdf
acyclovir-for-sarscov2-an-old-drug-with-a-new-purpose.pdfacyclovir-for-sarscov2-an-old-drug-with-a-new-purpose.pdf
acyclovir-for-sarscov2-an-old-drug-with-a-new-purpose.pdf
 
Contrast induced-Acute Kidney Injury
Contrast induced-Acute Kidney InjuryContrast induced-Acute Kidney Injury
Contrast induced-Acute Kidney Injury
 
11_Management Post operative Low Cardiac Output Syndrome.pdf
11_Management Post operative Low Cardiac Output Syndrome.pdf11_Management Post operative Low Cardiac Output Syndrome.pdf
11_Management Post operative Low Cardiac Output Syndrome.pdf
 
Sepsis
SepsisSepsis
Sepsis
 
ueda2012 metabolic memory-d.mgahed
ueda2012 metabolic memory-d.mgahedueda2012 metabolic memory-d.mgahed
ueda2012 metabolic memory-d.mgahed
 
NSAIDs and ICON-G
NSAIDs and ICON-GNSAIDs and ICON-G
NSAIDs and ICON-G
 
DCCT Learned Lessons
DCCT Learned LessonsDCCT Learned Lessons
DCCT Learned Lessons
 
Hemodynamic Puzzle
Hemodynamic PuzzleHemodynamic Puzzle
Hemodynamic Puzzle
 
Nguyen huu hoang ta
Nguyen huu hoang taNguyen huu hoang ta
Nguyen huu hoang ta
 
download-key-lessons-on-ldl-c-and-cv-risk.pptx
download-key-lessons-on-ldl-c-and-cv-risk.pptxdownload-key-lessons-on-ldl-c-and-cv-risk.pptx
download-key-lessons-on-ldl-c-and-cv-risk.pptx
 
Gliclazide - Revisiting evidence on a classic therapy - Dr. Rajiv Kovil.pptx
Gliclazide - Revisiting evidence on a classic therapy - Dr. Rajiv Kovil.pptxGliclazide - Revisiting evidence on a classic therapy - Dr. Rajiv Kovil.pptx
Gliclazide - Revisiting evidence on a classic therapy - Dr. Rajiv Kovil.pptx
 
Treatment for severe acute respiratory distress syndrome from covid 19
Treatment for severe acute respiratory distress syndrome from covid   19Treatment for severe acute respiratory distress syndrome from covid   19
Treatment for severe acute respiratory distress syndrome from covid 19
 
Focus on long acting opioid substitution therapy.pptx
Focus on long acting opioid substitution therapy.pptxFocus on long acting opioid substitution therapy.pptx
Focus on long acting opioid substitution therapy.pptx
 
Rao SV - AIMRADIAL 2013 - Bivalirudin and radial
Rao SV - AIMRADIAL 2013 - Bivalirudin and radialRao SV - AIMRADIAL 2013 - Bivalirudin and radial
Rao SV - AIMRADIAL 2013 - Bivalirudin and radial
 

Recently uploaded

A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
Dr. Jyothirmai Paindla
 
OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1
KafrELShiekh University
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Swastik Ayurveda
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
chandankumarsmartiso
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
Swastik Ayurveda
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
bkling
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Dr. Madduru Muni Haritha
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
Swastik Ayurveda
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 

Recently uploaded (20)

A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
 
OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 

DR. MOHAMMAD ABBAS- E-POSTER PRESENTATION.pptx

  • 1. ABSTRACT N0 -ABS0027 TITLE: CRTICAL ILLNESS POLYMYOPATHY IN COVID 19 PATIENTS. AUTHORS: DR MOHAMMAD ABBAS, DR HARISH M M NARAYANA HRUDAYALAYA HOSPITAL, BOMMASANDRA, BENGALURU-560022
  • 2. TITLE:CRTICAL ILLNESS POLYMYOPATHY IN COVID 19 PATIENTS. INTRODUCTION: COVID19disease aglobalpandemicwillberemembered for rapid onset respiratory failure requiring Oxygen therapy, Prolonged Mechanical ventilation and Proning. It required Prolonged duration of hospitalization, Inotropic supports, Antibiotics, Steroids, Fluctuation in Sugar levels and prolonged use of muscle relaxants for mechanical ventilation which is associated with increased incidence on Critical illness polymyopathy. Hence, we collected retrospective data of critically ill COVID-19 patients who developed from critical illness myopathy and assessed the effect of various risk factors and interventions like physiotherapy on the long-term outcome in these patients.
  • 3. METHODOLOGY: COVID19Positive August2020–December2020 Criticalillnesspolymyopathyclinically Anonymously, and all patient identifiers were removed to ensure confidentiality DATA COLLECTION. Demographic details, Vitals, dose of inotropes, Glasgow Coma Scale(GCS), SOFA scores at arrival, Glucose levels, Arterial blood gas analysis, Complete blood count, Electrolytes, and Use of antibiotics, Steroids, Hydroxychloroquine/chloroquine, Antivirals were collected. Use of interventions, and Various physiotherapy measures(re-education, long sitting on the bed, chair mobilization, walking, and gait balance) in terms of outcomes. TITLE:CRTICAL ILLNESS POLYMYOPATHY IN COVID 19 PATIENTS.
  • 4. RESULTS. RESULTS Survived (N= 7) Died (N= 4) P value Age (yrs) 59 ± 1.41 63 ± 4.24 0.24 Male (%) 5 (71.4%) 3 (75%) 0.72 Female 2 (28.6%) 1(25%) Weight, kg 80 ± 2.82 73±7.07 1 ICU stay* (No. of days) 41 (2) 26 (5) 0.57 Ventilator days 32.5 (11) 13 (1) 0.61 Ventilator Free days 9(15) 5(14.5) 0.67 P/F ratio† 179.57 ± 13.66 171 ± 39.04 0.60 PCO2, mmHg‡ 46.42 ± 7.43 48 ± 4.08 0.70 SOFA score§ 2.57 ± 0.97 2.75 ± 0.50 0.74 Neuromuscular relaxant Free days 17(17) 13.5(23) 0.75 Corticosteroid use, days 15.1±3.3 20.2±5.6 0.08 Polymyxin use, days 7.8±5.3 7.5±3.5 0.90 Colchicine use, days 8.3±3.8 9.5±1.9 0.58 Random Blood Sugar, mg/dl 140.50 ± 7.78 188.50 ± 21.92 0.86 Lactate, mmol/L 1.57 ± 0.53 2.25 ± 0.50 0.06 CRP, mg/L|| 92.50 ± 88.38 129 ± 152.73 0.50 LDH, Units/L** 641.50 ± 44.54 467.50 ± 567.80 0.24 Ferritin, ng/ml 565 ± 244.65 1042.50 ± 497.09 0.24 D-Dimer, ng/ml 2253 ± 654.78 2246 ± 2375.87 0.12 Survived (N= 7) Died (N= 4) P value Re education, number of days 16.29 ± 5.55 14.50 ± 4.12 0.59 Long Sitting, number of days 10.43 ± 3.15 2.75 ± 3.09 0.007 Chair mobilization, number of days 7.14 ± 1.95 2 ± 1.41 0.001 Standing, number of days 3.43 ± 3.15 0 0.06 Survived (N=7) Died (N=4) P value Dependency, Total (n,%) 1 (14.3%) 4 (100%) 0.02 Significant (n,%) 5 (71.4%) 0 DISCUSSION: One important finding in our case series was the effect of protocol-based physiotherapy interventions on survival. Physiotherapy
  • 5. CONCLUSION: In patients with COVID-19 related critical illness myopathy, use of protocol based physiotherapy interventions leads to improved survival. Further studies with larger population of cases are needed to draw a stronger conclusion. REFERENCES: 1. Critical Illness Polyneuropathy and Myopathy in COVID-19 Patients: A Prospective Observational Intensive Care Unit Cross-Sectional Cohort Study [Internet]. 2020 [cited 2021 Mar 18]. Available from: https://www.researchsquare.com. 2.Cabañes-Martínez L, Villadóniga M, González-Rodríguez L, Araque L, Díaz-Cid A, Ruz- Caracuel I, et al. Neuromuscular involvement in COVID-19 critically ill patients. Clin Neurophysiol. 2020;131:2809–16. TITLE:CRTICAL ILLNESS POLYMYOPATHY IN COVID 19 PATIENTS. LIMITATIONS Smaller sample size Definitive diagnostic methods not used.